Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Bruce Cozadd Sells 3,500 Shares

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Bruce Cozadd sold 3,500 shares of the stock in a transaction that occurred on Friday, October 3rd. The stock was sold at an average price of $140.00, for a total value of $490,000.00. Following the completion of the transaction, the director owned 408,826 shares in the company, valued at $57,235,640. This represents a 0.85% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Jazz Pharmaceuticals Price Performance

NASDAQ JAZZ opened at $139.48 on Friday. Jazz Pharmaceuticals PLC has a fifty-two week low of $95.49 and a fifty-two week high of $148.06. The stock’s 50-day moving average is $123.75 and its two-hundred day moving average is $115.66. The firm has a market cap of $8.46 billion, a P/E ratio of -20.73, a price-to-earnings-growth ratio of 8.65 and a beta of 0.28. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.62 and a quick ratio of 1.37.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($5.61) by ($2.64). Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The firm had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.05 billion. During the same quarter in the previous year, the firm posted $5.30 earnings per share. Jazz Pharmaceuticals’s quarterly revenue was up 2.1% compared to the same quarter last year. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. On average, analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently commented on JAZZ shares. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Jazz Pharmaceuticals in a research report on Saturday, September 27th. Morgan Stanley upped their price target on Jazz Pharmaceuticals from $163.00 to $167.00 and gave the company an “overweight” rating in a report on Wednesday, September 24th. Zacks Research upgraded Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Friday, August 15th. Needham & Company LLC restated a “buy” rating and set a $202.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, August 28th. Finally, Truist Financial upped their target price on Jazz Pharmaceuticals from $200.00 to $205.00 and gave the company a “buy” rating in a research note on Thursday, August 28th. Fourteen research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Jazz Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $178.93.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. GAMMA Investing LLC boosted its position in Jazz Pharmaceuticals by 30.7% in the 3rd quarter. GAMMA Investing LLC now owns 655 shares of the specialty pharmaceutical company’s stock valued at $86,000 after buying an additional 154 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of Jazz Pharmaceuticals by 1.6% during the second quarter. China Universal Asset Management Co. Ltd. now owns 12,383 shares of the specialty pharmaceutical company’s stock worth $1,314,000 after acquiring an additional 201 shares during the last quarter. Thrivent Financial for Lutherans lifted its stake in shares of Jazz Pharmaceuticals by 38.1% during the second quarter. Thrivent Financial for Lutherans now owns 19,720 shares of the specialty pharmaceutical company’s stock valued at $2,093,000 after acquiring an additional 5,440 shares during the period. Marex Group plc bought a new position in Jazz Pharmaceuticals in the second quarter valued at about $610,000. Finally, State of Wyoming increased its position in Jazz Pharmaceuticals by 21.4% in the second quarter. State of Wyoming now owns 4,029 shares of the specialty pharmaceutical company’s stock worth $428,000 after purchasing an additional 709 shares during the period. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.